Oscar Health shares rise to $30 but face margin pressure ahead, with cautious Buy rating and $37 target.

Oscar Health's stock has increased to around $30, reflecting strong recent performance. However, upcoming quarters are expected to see pressure on earnings per share (EPS) and margins due to risk adjustment transfers and plan mix changes. The medical loss ratio (MLR) is forecasted to rise to the mid-to-high seventies, with negative EPS expected despite flat SG&A costs balanced by tech efficiencies. The analyst assigns a Buy rating with a $37 price target based on a 15x P/E multiple on a probability-weighted $2.45 EPS, but advises a cautious, execution-focused approach going forward.